A Randomized, Open-Label, Comparative, Multi-Center Trial to Evaluate Contraceptive Efficacy, Cycle Control, Safety and Acceptability of a Monophasic Combined Oral Contraceptive (COC) Containing 2.5 mg Nomegestrol Acetate (NOMAC) and 1.5 mg Estradiol (E2) [estradiol/nomegestrol], Compared to a Monophasic COC Containing 3 mg Drospirenone (DRSP) and 30 µg Ethinyl Estradiol (EE) [ethinylestradiol/drospirenone]
Latest Information Update: 11 Feb 2022
At a glance
- Drugs Estradiol/nomegestrol (Primary) ; Drospirenone/ethinylestradiol
- Indications Pregnancy
- Focus Therapeutic Use
- Acronyms Samba
- Sponsors Organon
- 13 Jun 2019 Trial has been completed in UK and Spain.
- 20 Dec 2016 Results of pooled analysis of two studies (RUMBA and Samba) published in the Contraception
- 23 Jun 2012 Moos Menstrual Distress Questionnaire results presented at the 12th Congress of the European Society of Contraception.